Projected Income Statement: Summit Therapeutics Inc.

Forecast Balance Sheet: Summit Therapeutics Inc.

Forecast Balance Sheet - Summit Therapeutics Inc.
Fiscal Period: December 2023 2024 2025 2026 2027 2028
Net Debt 1 - - -529 -352 -138 -458
Change - - - 33.41% 60.8% -231.88%
Announcement Date 2/20/24 2/24/25 2/23/26 - - -
1GBP in Million
Estimates

Cash Flow Forecast: Summit Therapeutics Inc.

Fiscal Period: December 2024 2025 2026 2027 2028
CAPEX 1 0.11 0.4866 6.722 6.871 7.094
Change - 342.29% 1,281.57% 2.21% 3.25%
Free Cash Flow (FCF) 1 -112.6 -239.6 -501.9 -689.2 -555
Change - -112.87% -109.46% -37.31% 19.47%
Announcement Date 2/24/25 2/23/26 - - -
1GBP in Million
Estimates

Forecast Financial Ratios: Summit Therapeutics Inc.

Fiscal Period: December 2023 2024 2025 2026 2027 2028

Profitability

      
EBITDA Margin (%) - - - -49,439.25% -2,213.91% -104.81%
EBIT Margin (%) - - - -56,445.33% -2,807.78% -147.84%
EBT Margin (%) - - - -55,998.5% -2,728.47% -122.28%
Net margin (%) - - - -55,338.74% -2,595.35% -105.55%
FCF margin (%) - - - -42,564.24% -2,548.8% -143.76%
FCF / Net Income (%) - 64.31% 29.97% 76.92% 98.21% 136.21%

Profitability

      
ROA - - - - - -
ROE - -94.9% -206.1% -139.03% -1,429.93% 177.05%

Financial Health

      
Leverage (Debt/EBITDA) - - - - - -
Debt / Free cash flow - - - - - -

Capital Intensity

      
CAPEX / Current Assets (%) - - - 570.03% 25.41% 1.84%
CAPEX / EBITDA (%) - -0.1% -0.06% -1.15% -1.15% -1.75%
CAPEX / FCF (%) - -0.1% -0.2% -1.34% -1% -1.28%

Items per share

      
Cash flow per share 1 - - - - - -
Change - - - - - -
Dividend per Share 1 - - - - - -
Change - - - - - -
Book Value Per Share 1 - - 0.6293 0.254 0.025 0.402
Change - - - -59.64% -90.16% 1,508%
EPS 1 -0.7828 -0.2452 -1.066 -0.8244 -0.7962 -0.4547
Change - 68.67% -334.87% 22.7% 3.42% 42.89%
Nbr of stocks (in thousands) 700,843 737,448 771,150 799,764 799,764 799,764
Announcement Date 2/20/24 2/24/25 2/23/26 - - -
1GBP
Estimates
2026 *2027 *
P/E -9.79x -10.1x
PBR 31.8x 323x
EV / Sales 5,766x 259x
Yield - -

EPS & Dividend

EPS & Dividend - Summit Therapeutics Inc.


Y-o-Y evolution of P/E

Valuation ratios - P/E - Summit Therapeutics Inc.
 

Year-on-year evolution of the Yield

Valuation ratios - Yield - Summit Therapeutics Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
8.072GBP
Average target price
22.30GBP
Spread / Average Target
+176.27%
  1. Stock Market
  2. Stocks
  3. SMMT Stock
  4. Financials Summit Therapeutics Inc.